股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： RMB 360,593,720 備註： 第 1 頁 共 11 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | ...

Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 29.29% but a recent decline of 11.92% over the past 60 days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of Kailaiying's shareholders reached 60,100, an increase of 45.37% compared to the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - On November 4, Kailaiying's stock price fell by 2.02%, trading at 96.96 yuan per share, with a total market capitalization of 34.963 billion yuan. The stock saw a net outflow of 3.0292 million yuan in principal funds [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 8, where it recorded a net buy of -180 million yuan [1]. Business Overview - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services. The revenue composition includes 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1][2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2].

Group 1 - Norges Bank increased its stake in Kailaiying (06821.HK) by purchasing 213,700 shares at an average price of HKD 86.6001 per share, totaling approximately HKD 18.5064 million [1] - Following the purchase, Norges Bank's total shareholding rose to 3.7222 million shares, increasing its ownership percentage from 12.73% to 13.51% [1]

Group 1 - Norges Bank increased its stake in Kelaiying (002821) (06821) by 213,700 shares at a price of HKD 86.6001 per share, totaling approximately HKD 18.5064 million [1] - After the increase, Norges Bank's total shareholding in Kelaiying reached 3.7222 million shares, representing a holding percentage of 13.51% [1]

Core Viewpoint - Schroders PLC has reduced its stake in Kelaiying (002821) to 21.94% after selling 28,100 shares at a price of HKD 86.1644 per share, totaling approximately HKD 2.4212 million [1] Summary by Category Shareholding Changes - Schroders PLC sold 28,100 shares of Kelaiying on October 30, resulting in a decrease in its shareholding [1] - After the sale, Schroders PLC's total shareholding in Kelaiying is now 6.0458 million shares [1] - The new ownership percentage of Schroders PLC in Kelaiying is 21.94% [1]

Group 1 - Schroders PLC reduced its stake in Kelaiying (06821) by 28,100 shares at a price of HKD 86.1644 per share, totaling approximately HKD 2.4212 million [1] - After the reduction, Schroders PLC's latest holding is 6.0458 million shares, representing a holding percentage of 21.94% [1]

Core Viewpoint - Norges Bank increased its stake in Kairong (06821) by purchasing 213,700 shares at a price of HKD 86.6001 per share, totaling approximately HKD 18.5064 million, raising its total holdings to 3.7222 million shares, which represents 13.51% of the company [1] Summary by Category - **Share Purchase Details** - Norges Bank acquired 213,700 shares of Kairong at HKD 86.6001 per share [1] - The total investment amounted to approximately HKD 18.5064 million [1] - **Ownership Status** - Following the purchase, Norges Bank's total shareholding in Kairong increased to 3.7222 million shares [1] - The new ownership percentage stands at 13.51% [1]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 128.10 CNY per share [5][6]. Core Insights - The company achieved a revenue of 4.63 billion CNY in the first three quarters of 2025, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million CNY, up 12.66% year-on-year [2][3]. - The revenue for 2025 is expected to grow by 13%-15%, driven by a significant increase in the order delivery scale in Q4 compared to Q3 [2][3]. - The company is actively expanding its market presence, resulting in double-digit growth in new orders, particularly in the fields of peptides, oligonucleotides, and ADCs [3][4]. - The company has a rich pipeline of mid-to-late stage projects, which is expected to support long-term stable growth. There are 11 small molecule projects in the validation batch stage and 9 emerging business projects expected in the second half of 2025 [4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenues of 4.63 billion CNY, with a year-on-year increase of 11.82%. The net profit was 800 million CNY, reflecting a growth of 12.66% [2][3]. - The projected net profits for 2025 to 2027 are 1.13 billion CNY, 1.32 billion CNY, and 1.52 billion CNY, with year-on-year growth rates of 19.4%, 16.6%, and 15.1% respectively [5][11]. Market Expansion - The company is increasing its market development efforts, leading to a significant rise in new orders. The global investment in innovative drugs has seen a notable recovery, with VC&PE funding in 2025 increasing by 32% globally, 33% in the U.S., and 72% domestically [3]. Project Pipeline - The company has a strong project pipeline with over 10 mid-to-late stage clinical projects in popular targets such as peptides and small nucleic acids. Additionally, there are 8 NDA projects for toxin conjugates [4].

Core Viewpoint - The company, Kailaiying Pharmaceutical Group, reported a significant increase in revenue and operational efficiency in the third quarter of 2025, driven by growth in emerging business sectors and a positive outlook for the pharmaceutical industry [3]. Financial Performance - In the first three quarters of 2025, the company achieved total revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82% [3]. - Revenue from emerging businesses increased by 71.87%, while revenue from chemical macromolecule businesses grew by over 150% [3]. - Revenue from large pharmaceutical companies was 2.05 billion yuan, up 1.98%, and revenue from small and medium-sized pharmaceutical companies reached 2.58 billion yuan, up 21.14% [3]. - The overall gross profit margin for the company was 42.44%, with the gross profit margin for emerging businesses improving by 10.57 percentage points to 30.55% [3]. Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an annual revenue growth of 13% to 15% [3].

智通财经APP获悉，香港联交所最新资料显示，10月28日，Schroders PLC增持凯莱英(06821)8.74万股， 每股作价88.3138港元，总金额约为771.86万港元。增持后最新持股数目约为607.39万股，持股比例为 22.04%。 ...